In HER2-enriched BC (10–15% of all BC) the presence of amplified ERBB2, the HER2 gene, allows the use of targeted anti-HER2 therapy which has significantly improved the prognosis of HER2 + BC in recent years. This evidence concerns the gene ERBB2 and breast cancer.